Sitai: Proposes to Acquire 20% Equity Stake in Ruishi Pharmaceuticals

MetaMuskRat · 2026-03-24T19:07:08+00:00

People Finance News, March 23rd — Sitai(603520) announced on March 23rd that to enhance the comprehensive competitiveness of its CMO business, the company plans to acquire 20% equity stake in Jiangsu Ruishi Pharmaceutical Co., Ltd. (referred to as "Ruishi Pharmaceutical") held by Li Yongping for 10 million yuan. Ruishi Pharmaceutical has established in-depth cooperation with well-known CDMO enterprises and first-tier innovative pharmaceutical companies at home and abroad. Its product line covers multiple core raw materials including small molecule compounds, amino acids and their derivatives, and is committed to providing customers with stable, reliable, and high-quality material support from the early stage of drug research and development to the application stage, accelerating the new drug development process.

MetaMuskRat

2026-03-24 19:07:08

People’s Financial News, March 23 — Saitali (603520) announced on March 23 that to enhance the overall competitiveness of its CMO business, the company plans to acquire a 20% stake in Jiangsu Ruishi Pharmaceutical Co., Ltd. (“Ruishi Pharmaceutical”) held by Li Yongping for 10 million yuan. Ruishi Pharmaceutical has established deep collaborations with well-known domestic and international CDMO companies and leading original drug manufacturers. Its product lines include small molecule compounds, amino acids, and their derivatives, focusing on providing stable, reliable, high-quality materials from early drug development to submission stages, accelerating the development of new drugs.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.